TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33661958
Drug: Arms only
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms only exercise (upper body rowing exercise) performed with the same prescription as whole-body exercise.
Study: 32029509
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m2 administered on days 1, 4, and 8 of each chemotherapy course.
Study: 32029509
Drug: Bortezomib with
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib with standard chemotherapy.
Study: 32029509
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy without bortezomib.
Study: 33020094
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy combined with medication (CBT+M)
Study: 33020094
Drug: Medication-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-only group (M)
Study: 33172941
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin 20 μg in 50 mL sodium chloride 0.9% infused over 20 min
Study: 33172941
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin
Study: 35262556
Drug: Tooth bleaching
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth bleaching treatment
Study: 35262556
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with tooth color satisfaction and self‐perceived oral health
Study: 35864625
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) - 25 mg/kg bolus followed by 1 mg/kg/hour infusion
Study: 36263691
Drug: Agomelatine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine therapy (AT) with cognitive behavior therapy (CBT)
Study: 36263691
Drug: Agomelatine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine therapy (AT) without cognitive behavior therapy (CBT)
Study: 33198760
Drug: PM2.5 exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM2.5 exposure (mean: 37.8 μg/m3, SD 6.5)
Study: 33198760
Drug: Filtered air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered air (mean: 2.1 μg/m3, SD 2.6)
Study: 33227646
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DHA/day
Study: 34552200
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHA/day
Study: 32570710
Drug: Sugarcane flour
Normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugarcane flour (3 g per day)
Study: 32570710
Drug: Cellulose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose placebo (3 g per day)
Study: 35096107
Drug: Qinpi Tongfeng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinpi Tongfeng Formula (QPTFF) combined with bloodletting therapy
Study: 35096107
Drug: Colchicine tablets
Normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine tablets
Study: 34642699
Drug: mRNA-1273 25
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 25 MCG/0.25 ML Injectable Suspension, 6m through 5y
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 25 μg
Study: 34642699
Drug: mRNA-1273 100
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 100 MCG/0.5 ML Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 100 μg
Study: 32663912
Drug: mRNA-1273 250
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 250 μg
Study: 34560797
Drug: MAKS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAKS intervention (Motor, Activities of daily living, Cognitive and Social-communicative component) implemented in DCC
Study: 34622665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statin therapy and vorapaxar
Study: 32814661
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml fibrinogen and 25 U/ml thrombin (physiological as a control)
Study: 32814661
Drug: 40 mg/ml
Normalized name: fiber 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/ml fibrinogen and 250 U/ml thrombin (low adhesive)
Study: 32814661
Drug: 80 mg/ml
Normalized name: urea 180 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/ml fibrinogen and 250 U/ml thrombin (high adhesive)
Study: 35387238
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg twice a day before chemotherapy
Study: 32005277
Drug: Adaptive Servo-Ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive Servo-Ventilation (ASV) therapy
Study: 35109526
Drug: Doll therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doll therapy (DT)
Study: 32194222
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (2,700 mg/day)
Study: 36042488
Drug: 4% tetrasodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% tetrasodium EDTA (KiteLock Sterile Locking Solution™)
Study: 36042488
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (normal saline as a catheter locking solution)
Study: 32353277
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy (3-5 months) followed by management as usual
Study: 33931067
Drug: ACL repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACL repair using cortical button fixation and additional suture augmentation
Study: 35451359
Drug: Liver meat
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver meat balls (LMB) supplement 3 times a week for 90 days
Study: 35717050
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated and image guided radiation therapy (RT) with a dose of 50.4 Gy to primary PTV and 42 Gy to lymph node PTV, delivered over 28 fractions, with chemotherapy.
Study: 35717050
Drug: Customized immobilization
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized immobilization device and daily image guided RT.
Study: 32920824
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS)
Study: 32920824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical corticosteroid (TCS) and NB-UVB
Study: 32634435
Drug: Drug abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug abuse
Study: 34228505
Drug: Calaspargase (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calaspargase (2,500 IU/m2/dose, every 3 weeks for 10 doses)
Study: 34228505
Drug: Pegaspargase (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaspargase (2,500 IU/m2/dose, every 2 weeks for 15 doses)
Study: 35841057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nanofat subcutaneously and SVF intradermally
Study: 32703623
Drug: ReDS-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReDS-guided therapy
Study: 33712909
Drug: Balneological outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneological outpatient treatment (hydrotherapy and peloidotherapy)
Study: 36262374
Drug: PEMF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF therapy (1 mT for 10 min weekly for 16 weeks)
Study: 34488858
Drug: Subcutaneous IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IVM at 200 ?g/kg/48 h (Arm A)
Study: 34488858
Drug: Subcutaneous IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IVM at 200 ?g/kg/48 h and oral Zn 20mg/8 h (Arm B)
Study: 34488858
Drug: Oral IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IVM at 0.2 mg/kg/day (Arm C)
Study: 34488858
Drug: Oral IVM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IVM at 0.2 mg/kg/day and oral Zn 20mg/8 h (Arm D)
Study: 34488858
Drug: Oral Zn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Zn 20mg/8 h (Arm E)
Study: 33538345
Drug: Blue and
Normalized name: Aluminum Sesquichlorohydrate 0.17 mL in 1 mL TOPICAL LIQUID [CYZONE BLUE AND BLUE FOR HER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue and red light treatments consecutively on the same visit for 4 consecutive weeks
Study: 33662124
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (12-day postoperative taper)
Study: 34853102
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets
Study: 32879954
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NoTx)
Study: 33485468
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg with Algel-IMDG
Study: 33485468
Drug: 6 µg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 µg with Algel-IMDG
Study: 33485468
Drug: 6 µg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 µg with Algel
Study: 32481440
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg/day
Study: 36349973
Drug: Supplementary food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary food and anti-infective treatments
Study: 34881370
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated influenza vaccine (LAIV) administered at enrolment (day 0)
Study: 34881370
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (LAIV administered at the end of active follow-up, day 21)
Study: 36428011
Drug: Control pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control pharmacotherapy trial
Study: 38914694
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g glucose
Study: 33284114
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of intradermal f-IPV (administered at 14 and 36 weeks)
Study: 33284114
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of intramuscular IPV (administered at 14 and 36 weeks)
Study: 33284114
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of intradermal f-IPV (administered at 10, 14, and 36 weeks)
Study: 33284114
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of intramuscular IPV (administered at 10, 14, and 36 weeks)
Study: 32022371
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral temazepam
Study: 32588515
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/day for 6 months plus celecoxib 200 mg/day for 3 months
Study: 32588515
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/day for 6 months
Study: 34953184
Drug: Basic periodontal
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic periodontal therapy only
Study: 33292916
Drug: Videoconference administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Videoconference administration of neuropsychological measures
Study: 33292916
Drug: In-person administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person administration of neuropsychological measures
Study: 36471186
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise training (CT)
Study: 32496902
Drug: Intrathecal Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Triple Therapy (ITT)
Study: 34994794
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy modalities
Study: 34789000
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive atraumatic restorative treatment and the Hall technique approaches (ART-HT)
Study: 32126156
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Pain (CBT-P)
Study: 32537740
Drug: Utilization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utilization of the ECG Belt to guide implant as well as postimplant programming
Study: 36226977
Drug: Ruxolitinib 15
Normalized name: ruxolitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 15 mg
Study: 36226977
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg
Study: 33809796
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium meal plan (<0.95 mg/kcal)
Study: 33809796
Drug: Typical sodium
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical sodium meal plan (>2 mg/kcal)
Study: 32406601
Drug: Colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.75 g daily
Study: 37027137
Drug: Taking sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking sleep medications once or twice a week
Study: 37027137
Drug: Taking sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking sleep medications less than once a week
Study: 36229579
Drug: Repeat sequential
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat sequential two FLOX cycles and two immune checkpoint blockade (ICB) cycles
Study: 35841234
Drug: Soticlestat (≤300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat (≤300 mg twice daily, weight-adjusted)
Study: 34090216
Drug: Olive oil-based
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil-based intravenous lipid emulsion (OO-based IVLE)
Study: 34090216
Drug: Soybean oil-based
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil-based intravenous lipid emulsion (SO-based IVLE)
Study: 33988337
Drug: Standard-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose trivalent inactivated influenza vaccination (SDTIIV)
Study: 33988337
Drug: Double-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose trivalent inactivated influenza vaccination (DDTIIV)
Study: 33988337
Drug: Booster-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster-dose trivalent inactivated influenza vaccination (BDTIIV)
Study: 36458916
Drug: Inhaled sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled sargramostim (125 mcg twice daily for 5 days)
Study: 34940806
Drug: 20-Valent Pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-Valent Pneumococcal Conjugate Vaccine (PCV20)
Study: 34940806
Drug: 13-Valent Pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
Study: 34940806
Drug: 23-Valent Polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-Valent Polysaccharide Vaccine (PPSV23)
Study: 39359014
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg twice daily for 3 months
Study: 35766976
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity
Study: 35972855
Drug: Islatravir 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.25 mg with doravirine and lamivudine
Study: 35972855
Drug: Islatravir 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.75 mg with doravirine and lamivudine
Study: 32006650
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue photodynamic therapy (MB-PDT) applied twice a week for four weeks
Study: 32006650
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone valerate ointment 100 mg applied three times per day for four weeks
Study: 35358428
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with artemether–lumefantrine plus amodiaquine
Study: 35766202
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection (intra and periarticular) of methylprednisolone acetate 40 mg and local anesthetic
Study: 35766202
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of methylprednisolone acetate 40 mg and local anesthetic
Study: 33624730
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg body mass)
Study: 34594197
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (manual pressure release of myofascial trigger points)
Study: 35918731
Drug: Focused, expert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused, expert medication management intervention including in-person consultation and virtual care follow-up.
Study: 34311606
Drug: Single alcoholic
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single alcoholic beverage administration (placebo 0.00%, low 0.03%, moderate 0.06%, high 0.09%)
Study: 34311606
Drug: Cumulative alcoholic
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative alcoholic administration method (placebo followed by three alcoholic drinks)
Study: 32279615
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel plus herbal extract gel (Allium cepa, Centella Asiatica, Aloe vera and Paper Mulberry)
Study: 32522282
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg x 1 for Day 1-3, 250 mg x 1 for Day 4-15) and Hydroxychloroquine (200 mg x 2 for Day 1-15)
Study: 32522282
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + placebo
Study: 33090733
Drug: BMS-986166 (0.75-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986166 (0.75-5.0 mg single dose and 0.25-1.5 mg/day repeated dose)
Study: 33090733
Drug: BMS-986166 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986166 (0.5 mg/day)
Study: 32080133
Drug: Routine surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine surgical treatment without 3D printing
Study: 35603798
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) with compression therapy
Study: 35603798
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + compression therapy alone
Study: 33825020
Drug: Dental spray
Normalized name: Orasep Dental Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental spray
Study: 33825020
Drug: Toothpaste gel
Normalized name: ProDenRx Gel Toothpaste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste gel
Study: 33825020
Drug: Mouth rinsing
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth rinsing and spray application
Study: 33859411
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning framework for analyzing Cytosponge-TFF3 test samples; specific dosage and duration not mentioned.
Study: 35360551
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) treatment
Study: 32781086
Drug: Aldafermin 1
Normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 1 mg daily for 24 weeks
Study: 34649459
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic Acid (Aspirin)
Study: 32237205
Drug: Gynecologic cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynecologic cancer patients pre-radiation therapy
Study: 32237205
Drug: Gynecologic cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynecologic cancer patients post-radiation therapy
Study: 33586087
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy with gustative‐thermic‐tactile stimulation (group A)
Study: 34530882
Drug: Weekly SMS-questions
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS-questions about pain frequency and pain intensity
Study: 33079199
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 50% efficacy
Study: 33079199
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 1 year protection duration